Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences has demonstrated expanding operating margins, gaining 100 basis points in alignment with expectations, which bodes well for long-term profitability. The company is targeting an impressive average annual sales growth of approximately 10% excluding foreign exchange, driven by a robust portfolio of structural heart therapies and anticipated increases in procedure volumes. Additionally, the resurgence of the transcatheter aortic valve replacement (TAVR) segment, coupled with positive clinical outcomes and new launches like the Cordella heart failure monitoring device, positions Edwards for continued momentum and potential upward revisions in financial projections.

Edwards Lifesciences faces significant risks that may negatively impact its stock performance, primarily due to an uncertain growth outlook for its transcatheter aortic valve replacement (TAVR) business and a potentially smaller total addressable market than previously projected. Additionally, the firm's innovation pipeline for minimally invasive tricuspid and mitral valve repair products may experience delays, further hindering revenue contributions. External pressures such as intensified competition, challenging global regulatory environments, and adverse macro factors could exacerbate revenue growth headwinds, leading to lower-than-expected guidance for key sales metrics through 2026.